Publication | Open Access

Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes

Tumoral PathologyPhase IiMedicinePathologyGynecologyFallopian TubeOral GimatecanCancer TreatmentOncologyRadiation OncologyOral CancerOvarian Cancer